Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Synthesis and Biological Evaluation of Novel 3'-Difluorovinyl Taxoids.

Kuznetsova L, Sun L, Chen J, Zhao X, Seitz J, Das M, Li Y, Veith JM, Pera P, Bernacki RJ, Xia S, Horwitz SB, Ojima I.

J Fluor Chem. 2012 Nov 1;143:177-188. Epub 2012 Jul 28.

2.

Investigation of 3'-debenzoyl-3'-(3-([¹²⁴I]-iodobenzoyl))paclitaxel analog as a radio-tracer to study multidrug resistance in vivo.

Sajjad M, Riaz U, Yao R, Bernacki RJ, Abouzied M, Erb DA, Chaudhary ND, Veith JM, Georg GI, Nabi HA.

Appl Radiat Isot. 2012 Aug;70(8):1624-31. doi: 10.1016/j.apradiso.2012.03.008. Epub 2012 Mar 24.

PMID:
22738838
3.

Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer.

Shah DK, Veith J, Bernacki RJ, Balthasar JP.

Cancer Chemother Pharmacol. 2011 Oct;68(4):951-8. doi: 10.1007/s00280-011-1566-3. Epub 2011 Feb 9.

PMID:
21305289
4.

Design and synthesis of de novo cytotoxic alkaloids by mimicking the bioactive conformation of paclitaxel.

Sun L, Veith JM, Pera P, Bernacki RJ, Ojima I.

Bioorg Med Chem. 2010 Oct 1;18(19):7101-12. doi: 10.1016/j.bmc.2010.07.069. Epub 2010 Aug 6.

5.

Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy.

Shah DK, Shin BS, Veith J, Tóth K, Bernacki RJ, Balthasar JP.

J Pharmacol Exp Ther. 2009 May;329(2):580-91. doi: 10.1124/jpet.108.149443. Epub 2009 Feb 20.

6.

Design, synthesis, and biological evaluation of novel C14-C3'BzN-linked macrocyclic taxoids.

Sun L, Geng X, Geney R, Li Y, Simmerling C, Li Z, Lauher JW, Xia S, Horwitz SB, Veith JM, Pera P, Bernacki RJ, Ojima I.

J Org Chem. 2008 Dec 19;73(24):9584-93. doi: 10.1021/jo801713q.

7.

Metronomic chemotherapy and tumor immunomodulation.

Bernacki RJ.

Cancer Biol Ther. 2008 Apr;7(4):602. No abstract available.

PMID:
18614855
8.

Design, synthesis, and biological evaluation of new-generation taxoids.

Ojima I, Chen J, Sun L, Borella CP, Wang T, Miller ML, Lin S, Geng X, Kuznetsova L, Qu C, Gallager D, Zhao X, Zanardi I, Xia S, Horwitz SB, Mallen-St Clair J, Guerriero JL, Bar-Sagi D, Veith JM, Pera P, Bernacki RJ.

J Med Chem. 2008 Jun 12;51(11):3203-21. doi: 10.1021/jm800086e. Epub 2008 May 9.

9.

Syntheses and Structure-Activity Relationships of Novel 3'-Difluoromethyl and 3'-Trifluoromethyl-Taxoids.

Kuznetsova LV, Pepe A, Ungureanu IM, Pera P, Bernacki RJ, Ojima I.

J Fluor Chem. 2008;129(9):817-828.

10.

Modeling the combination of amphotericin B, micafungin, and nikkomycin Z against Aspergillus fumigatus in vitro using a novel response surface paradigm.

Brun YF, Dennis CG, Greco WR, Bernacki RJ, Pera PJ, Bushey JJ, Youn RC, White DB, Segal BH.

Antimicrob Agents Chemother. 2007 May;51(5):1804-12. Epub 2007 Feb 26.

11.

The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells.

Brooks TA, O'Loughlin KL, Minderman H, Bundy BN, Ford LA, Vredenburg MR, Bernacki RJ, Priebe W, Baer MR.

Invest New Drugs. 2007 Apr;25(2):115-22. Epub 2006 Oct 28.

PMID:
17072745
12.

Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease.

Dennis CG, Greco WR, Brun Y, Youn R, Slocum HK, Bernacki RJ, Lewis R, Wiederhold N, Holland SM, Petraitiene R, Walsh TJ, Segal BH.

Antimicrob Agents Chemother. 2006 Feb;50(2):422-7.

13.

Syntheses and evaluation of novel fatty acid-second-generation taxoid conjugates as promising anticancer agents.

Kuznetsova L, Chen J, Sun L, Wu X, Pepe A, Veith JM, Pera P, Bernacki RJ, Ojima I.

Bioorg Med Chem Lett. 2006 Feb 15;16(4):974-7. Epub 2005 Nov 18.

PMID:
16298526
14.

Use of the tubulin bound paclitaxel conformation for structure-based rational drug design.

Geney R, Sun L, Pera P, Bernacki RJ, Xia S, Horwitz SB, Simmerling CL, Ojima I.

Chem Biol. 2005 Mar;12(3):339-48.

15.

Design, synthesis and structure-activity relationships of novel taxane-based multidrug resistance reversal agents.

Ojima I, Borella CP, Wu X, Bounaud PY, Oderda CF, Sturm M, Miller ML, Chakravarty S, Chen J, Huang Q, Pera P, Brooks TA, Baer MR, Bernacki RJ.

J Med Chem. 2005 Mar 24;48(6):2218-28.

PMID:
15771464
16.

A phase I and pharmacokinetic study of BAY59: a novel taxane.

Ramnath N, Hamm J, Schwartz G, Holden S, Eckhardt SG, Vredenburg MR, Bernacki RJ, Lathia C, Kanter P, Creaven PJ.

Oncology. 2004;67(2):123-9.

PMID:
15539916
17.

Design and synthesis of de novo cytotoxic alkaloids through mimicking taxoid skeleton.

Geng X, Geney R, Pera P, Bernacki RJ, Ojima I.

Bioorg Med Chem Lett. 2004 Jul 5;14(13):3491-4.

PMID:
15177459
18.

Structure-activity analysis of taxane-based broad-spectrum multidrug resistance modulators.

Brooks TA, Kennedy DR, Gruol DJ, Ojima I, Baer MR, Bernacki RJ.

Anticancer Res. 2004 Mar-Apr;24(2A):409-15.

19.

Synthesis, molecular modeling, and evaluation of nonphenolic indole analogs of mycophenolic acid.

El-Araby ME, Bernacki RJ, Makara GM, Pera PJ, Anderson WK.

Bioorg Med Chem. 2004 Jun 1;12(11):2867-79.

PMID:
15142547
20.

Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023.

Minderman H, Brooks TA, O'Loughlin KL, Ojima I, Bernacki RJ, Baer MR.

Cancer Chemother Pharmacol. 2004 May;53(5):363-9. Epub 2004 Jan 27.

PMID:
15060738
21.

Structure-activity relationships of ring C-secotaxoids. 1. Acylative modifications.

Appendino G, Bettoni P, Noncovich A, Sterner O, Fontana G, Bombardelli E, Pera P, Bernacki RJ.

J Nat Prod. 2004 Feb;67(2):184-8.

PMID:
14987056
22.

Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest.

Ling X, Bernacki RJ, Brattain MG, Li F.

J Biol Chem. 2004 Apr 9;279(15):15196-203. Epub 2004 Jan 13.

23.

Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.

Brooks TA, Minderman H, O'Loughlin KL, Pera P, Ojima I, Baer MR, Bernacki RJ.

Mol Cancer Ther. 2003 Nov;2(11):1195-205. Erratum in: Mol Cancer Ther. 2004 Jan;3(1):101. Brooks, Tracy [corrected to Brooks, Tracy A].

24.

Synthesis and biological evaluation of 2'-methyl taxoids derived from baccatin III and 14beta-OH-baccatin III 1,14-carbonate.

Battaglia A, Bernacki RJ, Bertucci C, Bombardelli E, Cimitan S, Ferlini C, Fontana G, Guerrini A, Riva A.

J Med Chem. 2003 Nov 6;46(23):4822-5.

PMID:
14584931
25.

High-resolution magnetic resonance imaging of the efficacy of the cytosine analogue 1-[2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl]-N(4)-palmitoyl cytosine (CS-682) in a liver-metastasis athymic nude mouse model.

Wu M, Mazurchuk R, Chaudhary ND, Spernyak J, Veith J, Pera P, Greco W, Hoffman RM, Kobayashi T, Bernacki RJ.

Cancer Res. 2003 May 15;63(10):2477-82.

26.
27.

Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate.

Leontieva OV, Preobrazhenskaya MN, Bernacki RJ.

Invest New Drugs. 2002 Feb;20(1):35-48.

PMID:
12003193
28.

Design, synthesis and biological activity of novel C2-C3' N-Linked macrocyclic taxoids.

Ojima I, Geng X, Lin S, Pera P, Bernacki RJ.

Bioorg Med Chem Lett. 2002 Feb 11;12(3):349-52.

PMID:
11814794
29.

Modulation of human mammary cell sensitivity to paclitaxel by new quinoline sulfonamides.

Chibale K, Ojima I, Haupt H, Geng X, Pera P, Bernacki RJ.

Bioorg Med Chem Lett. 2001 Sep 17;11(18):2457-60.

PMID:
11549446
30.

Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.

Vredenburg MR, Ojima I, Veith J, Pera P, Kee K, Cabral F, Sharma A, Kanter P, Greco WR, Bernacki RJ.

J Natl Cancer Inst. 2001 Aug 15;93(16):1234-45.

PMID:
11504769
31.
32.

In vitro antitumor activity of 9-nitro-camptothecin as a single agent and in combination with other antitumor drugs.

Bernacki RJ, Pera P, Gambacorta P, Brun Y, Greco WR.

Ann N Y Acad Sci. 2000;922:293-7.

PMID:
11193904
33.

Syntheses and biological activity of C-3'-difluoromethyl-taxoids.

Ojima I, Lin S, Slater JC, Wang T, Pera P, Bernacki RJ, Ferlini C, Scambia G.

Bioorg Med Chem. 2000 Jul;8(7):1619-28.

PMID:
10976509
34.

Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy.

Dimitroff CJ, Klohs W, Sharma A, Pera P, Driscoll D, Veith J, Steinkampf R, Schroeder M, Klutchko S, Sumlin A, Henderson B, Dougherty TJ, Bernacki RJ.

Invest New Drugs. 1999;17(2):121-35.

PMID:
10638483
35.

Synthesis and structure-activity relationships of new second-generation taxoids.

Ojima I, Wang T, Miller ML, Lin S, Borella CP, Geng X, Pera P, Bernacki RJ.

Bioorg Med Chem Lett. 1999 Dec 20;9(24):3423-8.

PMID:
10617084
36.

Cell surface n-acetylneuraminic acid alpha2,3-galactoside-dependent intercellular adhesion of human colon cancer cells.

Dimitroff CJ, Pera P, Dall'Olio F, Matta KL, Chandrasekaran EV, Lau JT, Bernacki RJ.

Biochem Biophys Res Commun. 1999 Mar 24;256(3):631-6.

PMID:
10080950
37.

New taxanes as highly efficient reversal agents for multidrug resistance in cancer cells.

Ojima I, Bounaud PY, Takeuchi C, Pera P, Bernacki RJ.

Bioorg Med Chem Lett. 1998 Jan 20;8(2):189-94.

PMID:
9871652
38.

Cancer metastasis: a search for therapeutic inhibition.

Dimitroff CJ, Sharma A, Bernacki RJ.

Cancer Invest. 1998;16(4):279-90. Review.

PMID:
9589037
39.

Effects of novel spermine analogues on cell cycle progression and apoptosis in MALME-3M human melanoma cells.

Kramer DL, Fogel-Petrovic M, Diegelman P, Cooley JM, Bernacki RJ, McManis JS, Bergeron RJ, Porter CW.

Cancer Res. 1997 Dec 15;57(24):5521-7.

40.

Antitumor efficacy of N1,N11-diethylnorspermine on a human bladder tumor xenograft in nude athymic mice.

Sharma A, Glaves D, Porter CW, Raghavan D, Bernacki RJ.

Clin Cancer Res. 1997 Aug;3(8):1239-44.

41.

Activity of paclitaxel liposome formulations against human ovarian tumor xenografts.

Sharma A, Mayhew E, Bolcsak L, Cavanaugh C, Harmon P, Janoff A, Bernacki RJ.

Int J Cancer. 1997 Mar 28;71(1):103-7.

42.

Synthesis and structure-activity relationships of nonaromatic taxoids: effects of alkyl and alkenyl ester groups on cytotoxicity.

Ojima I, Kuduk SD, Pera P, Veith JM, Bernacki RJ.

J Med Chem. 1997 Jan 31;40(3):279-85.

PMID:
9022794
43.

Syntheses and structure-activity relationships of taxoids derived from 14 beta-hydroxy-10-deacetylbaccatin III.

Ojima I, Slater JC, Kuduk SD, Takeuchi CS, Gimi RH, Sun CM, Park YH, Pera P, Veith JM, Bernacki RJ.

J Med Chem. 1997 Jan 31;40(3):267-78.

PMID:
9022793
44.
45.

Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.

Ojima I, Slater JC, Michaud E, Kuduk SD, Bounaud PY, Vrignaud P, Bissery MC, Veith JM, Pera P, Bernacki RJ.

J Med Chem. 1996 Sep 27;39(20):3889-96.

PMID:
8831755
46.

Inhibition of human HT-29 colon carcinoma cell adhesion by a 4-fluoro-glucosamine analogue.

Woynarowska B, Dimitroff CJ, Sharma M, Matta KL, Bernacki RJ.

Glycoconj J. 1996 Aug;13(4):663-74.

PMID:
8872124
47.

Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.

Sharma A, Straubinger RM, Ojima I, Bernacki RJ.

J Pharm Sci. 1995 Dec;84(12):1400-4.

PMID:
8748320
48.

Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers.

Pendyala L, Kidani Y, Perez R, Wilkes J, Bernacki RJ, Creaven PJ.

Cancer Lett. 1995 Nov 6;97(2):177-84.

PMID:
7497460
50.

Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion.

Bernacki RJ, Oberman EJ, Seweryniak KE, Atwood A, Bergeron RJ, Porter CW.

Clin Cancer Res. 1995 Aug;1(8):847-57.

Supplemental Content

Loading ...
Support Center